Cytosorbents Corp

This non-binding advisory proposal asks stockholders to approve the Company’s disclosed compensation for its named executive officers (NEOs). Management is submitting the Say-on-Pay vote as required by Section 14A of the Exchange Act and to solicit stockholder feedback, although the result will not be binding on the Board or the Compensation Committee. The Board characterizes its executive pay program as performance-based and intended to attract, retain and motivate experienced executives through a mix of base salary, discretionary cash bonuses, and equity compensation (restricted stock units and stock options), with awards tied to corporate and individual performance objectives. The proxy highlights recent compensation actions including temporary salary reductions in 2024, deferred cash bonuses pending liquidity determinations, and awards granted to align interests and retain key executives. Management emphasizes that the Compensation Committee will review the voting outcome and consider stockholder concerns in future compensation decisions. Key governance context includes the Company’s status as a small-cap life sciences firm competing for talent and capital, and the Compensation Committee’s use of market data and committee oversight in setting pay. From an investor perspective, important evaluation points include the pay-for-performance linkage (disclosed in the CD&A and Pay vs. Performance tables), the use of equity-based incentives that vest over multiple years, and the existence of deferred or contingent cash payouts tied to liquidity. Although the Board recommends a FOR vote to affirm alignment with stockholder interests, the advisory nature of the vote means that continued engagement and disclosure changes are the principal mechanisms by which shareholders can influence future pay practices.

This management proposal seeks stockholder authorization to amend the Company’s Certificate of Incorporation so the Board may, within one year of approval, combine outstanding shares at a ratio between 1-for-5 and 1-for-20 at its discretion. The Board’s stated principal rationale is to increase the per-share market price to address non-compliance with Nasdaq’s $1.00 minimum bid price requirement and to preserve the Company’s Nasdaq listing, which management views as important for liquidity, visibility, and access to capital. The proxy provides context that the Company previously received a Nasdaq notice of non-compliance and has an extension through September 28, 2026 to regain compliance; the Board retains discretion whether and when to effect the split and will consider market price trends and other factors in choosing the ratio. If implemented, the split would proportionally reduce outstanding shares and increase the per-share price but would not change the economic ownership percentages of stockholders aside from fractional-share rounding which the Company will round up to the nearest whole share. The proxy also outlines risks: the split may not produce a sustained price increase, could reduce liquidity and increase transaction costs for odd-lot holders, and could have anti-takeover implications because it effectively increases the number of authorized but unissued shares available for issuance. Management frames the split as a flexible tool to maintain listing and potentially broaden institutional interest, while preserving Board control over timing and exact ratio to respond to market conditions. From an analytical standpoint, investors should weigh the regulatory imperative to address Nasdaq noncompliance against the historical mixed outcomes of reverse splits—recognizing potential benefits for listing and capital raising but also the risk that market forces may quickly erode any mechanical price increase and that reduced float could concentrate ownership and lower liquidity.

This proposal asks stockholders to grant the Company the procedural authority to adjourn the Annual Meeting (if necessary) to a later date or time to solicit additional proxies when there are insufficient votes to approve one or more proposals. Such adjournments are a common governance mechanism that allow management and the Board to continue outreach, present updated information to investors if appropriate, and attempt to secure the necessary majority votes without abandoning the underlying proposals. The proxy statement makes clear that any adjournment for solicitation purposes would permit stockholders who previously submitted proxies to revoke them in accordance with the stated revocation procedures, preserving shareholder rights. The vote required is a majority of shares present or represented and entitled to vote on the matter at the meeting, and abstentions are not counted as votes cast for or against this adjournment proposal. Management argues that approval is prudent because it prevents an otherwise successful proposal from failing due to temporary shortfalls in votes and helps avoid the disruptive alternative of rescheduling or cancelling company business. Analysts should note potential tactical uses: while adjournments are typically benign, they can extend the timeframe for contested solicitations or activist engagement and may signal management’s expectations about close votes. The Board’s unanimous recommendation for a FOR vote reflects a desire to preserve flexibility and reduce the risk that necessary corporate actions will be blocked by procedural shortfalls. From a governance perspective, investors may consider whether the Company has appropriate communication plans and whether any adjournment would be used solely for constructive outreach to holders or could be part of broader defensive tactics.